In the introduction to the above articleReference Collins, Hartsfield, Cleary, Kenney, Veve and Brockhaus 1 , the authors intended to communicate that cefazolin 2g concentrations achieve therapeutic concentrations at the end of infusion that are relevant to most Enterobacterales. In the original publication, methicillin-susceptible S. aureus was incorrectly described as having a Clinical & Laboratory Standards Institute cefazolin-specific susceptible breakpoint.
Changes should be made to two sentences in the article, as shown below. The correct, updated text appears in bold.
On the first page of the article:
The authors concluded that cefazolin 2 g exposures were insufficient based upon a selected pharmacokinetic target of ≥32 mcg/mL; however, mean intraoperative serum concentrations prior to their 3-h redosing interval ranged from 17.1 to 24.3 mcg/mL, exceeding the current Clinical Laboratory Standards Institute (CLSI) susceptibility breakpoint of ≤2 mcg/mL for Enterobacterales, including Escherichia coli.
On the fourth page of the article, in the discussion section:
Although a reduction in cefazolin exposure is observed at greater BMI, other pharmacokinetic data suggest cefazolin concentrations at the end of surgery may be sufficient to achieve 4 times a MIC90 of 1 mcg/mL for Staphylococcus aureus and contemporary CLSI breakpoint of ≤2 mcg/mL for Enterobacterales.
The authors apologize for the error.
